Nuwellis Inc(NUWE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 5:08 AM ET (Korea 10/21 18:08)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -136.06 | Insider Own | 14.52% | Shs Outstand | 3.6M | Perf Week | -11.51% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.1M | Perf Month | -37.11% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 0.57% | Short Float | 5.37% | Perf Quarter | -80.72% |
| Income | -0.01B | P/S | 0.22 | EPS this Y | - | Inst Trans | 5.87% | Short Ratio | 0.04 | Perf Half Y | -98.63% |
| Sales | 0.01B | P/B | - | EPS next 5Y | - | ROA | -123.57% | Short Interest | 0.17M | Perf YTD | -99.1% |
| Book/sh | -3.58 | P/C | 0.51 | EPS past 3/5Y | 94.09% 88.99% | ROE | -609.44% | 52W High | -99.68% ($172.90) | Perf Year | -99.55% |
| Cash/sh | 1.07 | P/FCF | - | Sales past 3/5Y | -1.08% 2.14% | ROIC | - | 52W Low | 23.65% ($0.44) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 88.88% | Gross Margin | 69.69% | Volatility(W/M) | 13.67% 8.65% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -0.19 | Sales Y/Y TTM | 8.36% | Oper. Margin | -142.87% | ATR (14) | 0.09 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.54 | EPS Q/Q | 98.75% | Profit Margin | -125.57% | RSI (14) | 30.8 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.97 | Sales Q/Q | 14.14% | SMA20 | -19.08% ($0.68) | Beta | 0.04 | Target Price | $16170 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -36.04% ($0.86) | Rel Volume | 0.01 | Prev Close | $0.56 |
| Employees | 38 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -98.12% ($29.26) | Avg Volume(3M) | 4.27M | Price | $0.55 |
| IPO | 2012/2/16 | Option/Short | No/Yes | Trades | 131 | Volume | 28,773 | Change | -1.52% |
💙 A medical device company developing fluid removal systems for heart failure patients. It focuses on ultrafiltration therapy systems for treating severe heart failure and pediatric urinary incontinence.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
NUWE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $22. Peers typically go for $145.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.6%.
Tap to view numbers
It ranks #140 of 142 in the industry
Based on market cap of $2M.
FAQ
What kind of company is NUWE?
NUWE belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NUWE?
The market cap of NUWE is approximately $2M, ranking 5,807 within its sector.
What is the 52-week high and low for NUWE?
NUWE has recorded a 52-week high of $172.90 and a low of $0.44.
